» Articles » PMID: 33044176

Interaction Between BDNF Val66Met and APOE4 on Biomarkers of Alzheimer's Disease and Cognitive Decline

Overview
Publisher Sage Publications
Specialties Geriatrics
Neurology
Date 2020 Oct 12
PMID 33044176
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Whether brain-derived neurotrophic factor (BDNF) Met carriage impacts the risk or progression of Alzheimer's disease (AD) is unknown.

Objective: To evaluate the interaction of BDNF Met and APOE4 carriage on cerebral metabolic rate for glucose (CMRgl), amyloid burden, hippocampus volume, and cognitive decline among cognitively unimpaired (CU) adults enrolled in the Arizona APOE cohort study.

Methods: 114 CU adults (mean age 56.85 years, 38% male) with longitudinal FDG PET, magnetic resonance imaging, and cognitive measures were BDNF and APOE genotyped. A subgroup of 58 individuals also had Pittsburgh B (PiB) PET imaging. We examined baseline CMRgl, PiB PET amyloid burden, CMRgl, and hippocampus volume change over time, and rate of change in cognition over an average of 15 years.

Results: Among APOE4 carriers, BDNF Met carriers had significantly increased amyloid deposition and accelerated CMRgl decline in regions typically affected by AD, but without accompanying acceleration of cognitive decline or hippocampal volume changes and with higher baseline frontal CMRgl and slower frontal decline relative to the Val/Val group. The BDNF effects were not found among APOE4 non-carriers.

Conclusion: Our preliminary studies suggest that there is a weak interaction between BDNF Met and APOE4 on amyloid-β plaque burden and longitudinal PET measurements of AD-related CMRgl decline in cognitively unimpaired late-middle-aged and older adults, but with no apparent effect upon rate of cognitive decline. We suggest that cognitive effects of BDNF variants may be mitigated by compensatory increases in frontal brain activity-findings that would need to be confirmed in larger studies.

Citing Articles

Positive Allosteric Modulators of Trk Receptors for the Treatment of Alzheimer's Disease.

Forsell P, Parrado Fernandez C, Nilsson B, Sandin J, Nordvall G, Segerdahl M Pharmaceuticals (Basel). 2024; 17(8).

PMID: 39204102 PMC: 11357672. DOI: 10.3390/ph17080997.


Potential role of ɛ4 allele as a modifier for the association of Val66Met polymorphisms and cognitive impairment in community-dwelling older adults.

Ji S, Kang J, Han C, Xu X, Chen M, Chen J Front Aging Neurosci. 2024; 16:1330193.

PMID: 38374884 PMC: 10876185. DOI: 10.3389/fnagi.2024.1330193.


DAT1 and BDNF polymorphisms interact to predict Aβ and tau pathology.

Ciampa C, Morin T, Murphy A, La Joie R, Landau S, Berry A Neurobiol Aging. 2023; 133:115-124.

PMID: 37948982 PMC: 10872994. DOI: 10.1016/j.neurobiolaging.2023.10.009.


Impact of transcranial direct current stimulation on white matter microstructure integrity in mild cognitive impairment patients according to effect modifiers as risk factors for Alzheimer's disease.

Kang D, Wang S, Um Y, Kim S, Kim T, Kim D Front Aging Neurosci. 2023; 15:1234086.

PMID: 37744398 PMC: 10517264. DOI: 10.3389/fnagi.2023.1234086.


Neuroprotective and Disease-Modifying Effects of the Triazinetrione ACD856, a Positive Allosteric Modulator of Trk-Receptors for the Treatment of Cognitive Dysfunction in Alzheimer's Disease.

Parrado Fernandez C, Juric S, Backlund M, Dahlstrom M, Madjid N, Lidell V Int J Mol Sci. 2023; 24(13).

PMID: 37446337 PMC: 10342804. DOI: 10.3390/ijms241311159.


References
1.
Caselli R, Reiman E, Locke D, Hutton M, Hentz J, Hoffman-Snyder C . Cognitive domain decline in healthy apolipoprotein E epsilon4 homozygotes before the diagnosis of mild cognitive impairment. Arch Neurol. 2007; 64(9):1306-11. DOI: 10.1001/archneur.64.9.1306. View

2.
Kok E, Haikonen S, Luoto T, Huhtala H, Goebeler S, Haapasalo H . Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age. Ann Neurol. 2009; 65(6):650-7. DOI: 10.1002/ana.21696. View

3.
Lim Y, Villemagne V, Laws S, Ames D, Pietrzak R, Ellis K . BDNF Val66Met, Aβ amyloid, and cognitive decline in preclinical Alzheimer's disease. Neurobiol Aging. 2013; 34(11):2457-64. DOI: 10.1016/j.neurobiolaging.2013.05.006. View

4.
Morris J, Roe C, Xiong C, Fagan A, Goate A, Holtzman D . APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010; 67(1):122-31. PMC: 2830375. DOI: 10.1002/ana.21843. View

5.
Lamb Y, Thompson C, McKay N, Waldie K, Kirk I . The brain-derived neurotrophic factor (BDNF) val66met polymorphism differentially affects performance on subscales of the Wechsler Memory Scale - Third Edition (WMS-III). Front Psychol. 2015; 6:1212. PMC: 4538220. DOI: 10.3389/fpsyg.2015.01212. View